登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：600654 证券简称：中安科 公告编号：2025-071 1、2023年3月17日，公司召开第十一届董事会第六次会议审议通过了《关于〈公司2023年股票期权与限 制性股票激励计划（草案）〉及其摘要的议案》《关于〈公司2023年股票期权与限制性股票激励计划实 施考核管理办法〉的议案》《关于提请股东大会授权董事会办理公司股权激励计划有关事项的议案》， 公司独立董事对上述议案发表了明确同意的独立意见，律师出具了相应的法律意见书。 同日，公司召开了第十一届监事会第五次会议审议通过了《关于〈公司2023年股票期权与限制性股票激 励计划（草案）〉及其摘要的议案》《关于〈公司2023年股票期权与限制性股票激励计划实施考核管理 办法〉的议案》。 中安科股份有限公司 关于2023年股票期权与限制性股票激励计划 2025年第三季度自主行权结果暨股份变动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 本次行权股票数量：2025年第三季度，中安科股份有限公司（以下 ...

Core Viewpoint - The company has announced the repurchase and cancellation of 3,481,750 restricted shares due to the departure of nine incentive recipients who no longer qualify for the incentive program [2][14][18]. Group 1: Repurchase Details - The number of restricted shares to be repurchased is 3,481,750 shares [2]. - The repurchase price is set at the grant price of 1.25 yuan per share, totaling approximately 4,352,187.50 yuan [15]. - The funding for the repurchase will come entirely from the company's own funds [16]. Group 2: Approval Process - The repurchase has been authorized by the company's shareholders at the 2023 first extraordinary general meeting held on April 3, 2023 [4][18]. - The board of directors approved the repurchase at the 12th board meeting on August 12, 2025, without needing further shareholder approval [2][38]. Group 3: Impact on Share Capital - Following the repurchase, the total number of shares will decrease from 2,876,607,560 shares to 2,866,180,886 shares [18]. - The repurchase will not have a substantial impact on the company's financial status or operational results [19][22]. Group 4: Compliance and Legal Opinions - The repurchase complies with relevant laws, regulations, and the company's incentive plan [21][22]. - Legal opinions confirm that the necessary approvals and procedures have been followed for the repurchase [22].

证券代码：600654 证券简称：中安科 公告编号：2025-064 中安科股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ? 限制性股票回购注销数量为 3,481,750 股。 ? 根据公司于 2023 年 4 月 3 日召开的 2023 年第一次临时股东大会审议通过的 《关于提请股东大会授权董事会办理公司股权激励计划有关事项的议案》， 公司董事会就决定实施本次回购注销部分限制性股票等相关事宜已取得公 司股东大会合法授权，经公司董事会审议通过后无需再提交股东大会审议。 中安科股份有限公司（以下简称"公司"）于 2025 年 8 月 12 日召开公司第 十二届董事会第四次会议，审议并通过了《关于回购注销部分限制性股票的议案》， 同意对公司《2023 年股票期权与限制性股票激励计划》（以下简称"激励计划"） 首次授予和预留授予的部分已获授但尚未解除限售的限制性股票进行回购注销， 股份数量合计 3,481,750 股，回购价格为授予价格，即 1.25 元/股。现将有关事项 说明如下： 一、本次股权激励 ...

证券日报网讯 8月12日晚间，中安科发布公告称，公司于2025年8月12日召开公司第十二届董事会第四 次会议，审议并通过了《关于回购注销部分限制性股票的议案》，同意对公司《2023年股票期权与限制 性股票激励计划》（以下简称"激励计划"）首次授予和预留授予的部分已获授但尚未解除限售的限制性 股票进行回购注销，股份数量合计3，481，750股，回购价格为授予价格，即1.25元/股。 （文章来源：证券日报） ...

Core Points - The company has approved the second exercise period of its 2023 stock option and restricted stock incentive plan, allowing eligible participants to exercise their stock options [2][12][19] - A total of 35 participants are eligible to exercise 1,920,077 stock options at a price of 2.00 yuan per share [2][18][19] - The exercise period for these stock options is set from August 15, 2025, to April 16, 2026 [23] Summary by Sections Incentive Plan Approval and Implementation - The company held board and supervisory meetings on May 19, 2025, to approve the conditions for the second exercise period of the stock option plan [2] - The stock option plan was initially approved on March 17, 2023, with subsequent public disclosures and compliance checks [3][4] Stock Option Details - The stock options granted on April 17, 2023, totaled 10.15 million, with an exercise price of 2.00 yuan per share [14] - The actual number of stock options available for exercise in the second period is 1,920,077, with 35 eligible participants [19] Exercise Conditions and Procedures - The second exercise period's conditions have been met, allowing eligible participants to proceed with exercising their options [18] - The exercise will be facilitated by CITIC Securities as the main broker for the self-exercise process [19] Legal and Compliance Aspects - The company has received legal opinions confirming that the exercise and related actions comply with relevant regulations and internal policies [21][22] - The company has committed to timely disclosures regarding the exercise and any limitations on the exercise period [24]

中安科股份有限公司（以下简称"公司"）《2023 年股票期权与限制性股 票激励计划》（以下简称"本激励计划""激励计划"）首次授予股票期权第二 个行权期有效日期为 2025 年 4 月 17 日至 2026 年 4 月 16 日（行权日须为交易日）。 根据公司《激励计划》和中国证券登记结算有限责任公司上海分公司关于股票期 权自主行权的相关规定，公司《激励计划》首次授予股票期权的第二个行权期（期 权代码：1000000368）实际可行权期间为 2025 年 8 月 15 日至 2026 年 4 月 16 日。 结合公司 2025 年半年度报告披露计划的安排，现对公司《激励计划》处于 自主行权期的股票期权自主行权时间进行限制，具体情况如下： 票期权（期权代码：1000000368）的全部激励对象将限制行权。 申请办理限制行权相关事宜。 特此公告。 中安科股份有限公司 董事会 二〇二五年八月十二日 关于 2023 年股票期权与限制性股票激励计划 限制行权期间的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码：60 ...

Core Viewpoint - The announcement details the completion of the first unlock period for the reserved grant of restricted stocks under the 2023 stock option and restricted stock incentive plan of Zhong An Ke Co., Ltd, allowing 138 incentive objects to unlock a total of 4,558,560 shares [2][11][24]. Summary by Sections Incentive Plan Approval and Implementation - The board of directors approved the conditions for the second phase of stock options and the first phase of reserved grants on May 19, 2025, confirming that the conditions for unlocking the first phase of restricted stocks have been met [2][11]. - The incentive plan includes a total of 4,558,560 restricted stocks that can be unlocked, representing 0.16% of the company's total share capital [24]. Stock Grant and Unlock Conditions - The first unlock period for the reserved grant of restricted stocks began on April 2, 2024, and ended on April 1, 2025, meeting the necessary conditions for unlocking [14][24]. - The total number of restricted stocks granted in the first phase was 5,535,000 shares at a price of 1.25 yuan per share, with 138 individuals eligible for unlocking [3][24]. Listing and Trading of Unlocked Stocks - The unlocked restricted stocks will be listed and available for trading starting from July 14, 2025 [5][25]. - The total number of restricted stocks listed for trading is 4,558,560 shares, with specific restrictions on transfer for directors and senior management [25]. Legal Opinions and Compliance - The legal opinion confirms that all necessary approvals for the stock option exercise and the unlocking of restricted stocks have been obtained, and the actions comply with relevant regulations [26].

Core Viewpoint - The announcement details the first grant of stock options and restricted stock incentive plan for 2023, highlighting the conditions for the second unlock period of restricted stocks and the total number of shares that will be released for trading. Group 1: Incentive Plan Overview - The total number of restricted stocks to be released for trading is 11,183,850 shares, with 7,584,000 shares held by directors and senior management [3][24]. - The release date for the stocks is set for June 20, 2025 [3][25]. - The incentive plan was approved during the board meetings held on May 19, 2025, and includes 106 eligible participants for the second unlock period [3][12]. Group 2: Stock Grant Details - The first grant of restricted stocks occurred on April 17, 2023, with a total of 55,350,000 shares granted at a price of 1.25 yuan per share [5][14]. - The second unlock period for the restricted stocks began on April 17, 2025, and will last until the last trading day within 36 months from the grant date [15][24]. Group 3: Performance Conditions - The performance targets for the incentive plan include annual revenue and net profit benchmarks, with specific values set for each year from 2023 to 2025 [17][20]. - The company must meet these performance targets for the restricted stocks to be eligible for release, with a total of 106 participants meeting the conditions for the second unlock period [24][17]. Group 4: Share Structure Changes - Following the release of the restricted stocks, the total number of shares with limited sale conditions will decrease from 576,838,224 to 565,654,374 shares, while the total number of unrestricted shares will increase from 2,299,769,336 to 2,310,953,186 shares [25][24]. - The overall share capital remains unchanged at 2,876,607,560 shares [25].